{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:31Z","timestamp":1793496091148,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.euroneuro.2022.01.113","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T03:47:30Z","timestamp":1645242450000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-9691","authenticated-orcid":false,"given":"Laura E.","family":"De Wit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Wilting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Souverein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine C.G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2022.01.113_bib0001","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mds.23501","article-title":"Impulsivity and compulsivity in drug-na\u00efve patients with Parkinson\u2019s disease","volume":"26","author":"Antonini","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0002","first-page":"D1006","article-title":"The IUPHAR\/BPS guide to pharmacology in 2020: extending immunopharmacology content and introducing the IUPHAR\/MMV guide to malaria pharmacology","volume":"48","author":"Armstrong","year":"2020","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0003","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1530\/EC-18-0030","article-title":"Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist","volume":"7","author":"Athanasoulia-Kaspar","year":"2018","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0004","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00023210-200721120-00007","article-title":"Rotigotine Trandsermal Patch a review of its use in the management of Parkinson\u2019s disease","volume":"21","author":"Baldwin","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40264-017-0534-1","article-title":"Patient reporting in the EU: analysis of EudraVigilance data","volume":"40","author":"Banovac","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jad.2017.05.035","article-title":"Antidepressant-induced hypomania\/mania in patients with major depression: evidence from the BRIDGE-II-MIX study","author":"Barbuti","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0008","first-page":"93","article-title":"Detecting a safety signal of antipsychotic-associated pneumonia: a pharmacovigilance-pharmacodynamic study","author":"Cepaityte","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0009","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0010","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","article-title":"The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome","volume":"34","author":"Dang","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0014","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) - Module IX Addendum I \u2013 methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. 2017."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0015","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","article-title":"Impulsive and compulsive behaviors in Parkinson\u2019s disease","volume":"24","author":"Evans","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0016","doi-asserted-by":"crossref","unstructured":"Fusaroli M, Raschi E, Contin M, Sambati L, Menchetti M, Fioritti A, et\u00a0al. Impulsive conditions in Parkinson's disease: a pharmacosurveillance-supported list 2021. doi:10.1016\/j.parkreldis.2021.08.006.","DOI":"10.1016\/j.parkreldis.2021.08.006"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0017","first-page":"1","article-title":"Impulse control disorders and dopamine-related creativity: pathogenesis and mechanism, short review, and hypothesis","volume":"9","author":"Garcia-Ruiz","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1556\/JBA.3.2014.1.3","article-title":"Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration\u2019s Adverse Event database","volume":"3","author":"Gendreau","year":"2014","journal-title":"J. Behav. Addict."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0019","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1176\/appi.ajp.161.9.1537","article-title":"Antidepressants for bipolar depression: a systematic review of randomized, controlled trials","volume":"161","author":"Gijsman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000444","article-title":"Pathological gambling associated with aripiprazole or dopamine replacement therapy do patients share the same features? a review","volume":"36","author":"Grall-Bronnec","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/JCP.0000000000000367","article-title":"The pharmacovigilance syndrome","volume":"35","author":"Greenblatt","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0023","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/mds.21110","article-title":"Problematic gambling on dopamine agonists: not such a rarity","volume":"21","author":"Grosset","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0024","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2004.02.012","article-title":"Principles: receptor theory in pharmacology","volume":"25","author":"Kenakin","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00023210-200822050-00004","article-title":"Antiparkinsonian medication and pathological gambling","volume":"22","author":"Lader","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0027","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.psychres.2018.09.008","article-title":"Drug-induced gambling disorder: a not so rare but underreported condition","volume":"269","author":"Lanteri","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jns.2019.01.034","article-title":"Impulse control disorders in Parkinson\u2019s disease: a systematic review on risk factors and pathophysiology","volume":"398","author":"Latella","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0031","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders","volume":"396","author":"Mcintyre","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0032","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0033","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0034","doi-asserted-by":"crossref","unstructured":"Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, Fourrier-Reglat A, et\u00a0al. Effect of competition bias in safety signal generation analysis of a research database of spontaneous reports in France. 2012. doi:10.1007\/BF03261981.","DOI":"10.1007\/BF03261981"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0035","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/mds.23204","article-title":"Adverse drug reactions to dopamine agonists: a comparative study in the French pharmacovigilance database","volume":"25","author":"Perez-Lloret","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235591","article-title":"Increasing adverse drug reaction reporting-how can we do better?","volume":"15","author":"Potlog Shchory","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0037","first-page":"252","article-title":"The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?","volume":"6","author":"Roth","year":"2000","journal-title":"Neurosci"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0038","doi-asserted-by":"crossref","unstructured":"Schreiber L, Odlaug BL, Grant JE. Impulse control disorders: updated review of clinical characteristics and pharmacological management 2011;2. doi:10.3389\/fpsyt.2011.00001.","DOI":"10.3389\/fpsyt.2011.00001"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0039","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0040","first-page":"189","article-title":"Targeting dopamine and serotonin receptors for psychosis, mood, and beyond: so-called \u201cantipsychotics.\u201d Stahl\u2019s Essent","author":"Stahl","year":"2021","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0041","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pds.1323","article-title":"Data mining for signals in spontaneous reporting databases: proceed with caution","volume":"16","author":"Stephenson","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0042","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson\u2019s disease: from dyskinesias to impulse control disorders","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0043","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","article-title":"Medication-related impulse control and repetitive behaviors in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0044","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0046","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease, a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0047","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/NRL.0b013e3181e8868b","article-title":"Detection of impulse control disorders in Parkinson disease patients","volume":"16","author":"Weiss","year":"2010","journal-title":"Neurologist"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0048","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/CPJ.0b013e318278be9b","article-title":"Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease","volume":"2","author":"Weiss","year":"2012","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0049","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.euroneuro.2021.05.001","article-title":"Do cariprazine and brexpiprazole cause impulse control symptoms? A case\/non-case study","volume":"50","author":"Zazu","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0050","first-page":"1","article-title":"Risk of bleeding associated with antidepressants: impact of causality assessment and competition bias on signal detection","volume":"12","author":"Zeiss","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.113_bib0051","article-title":"Impulse control disorders in Parkinson\u2019s disease: epidemiology, pathogenesis and therapeutic strategies","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T18:56:42Z","timestamp":1652381802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":51,"alternative-id":["S0924977X22001225"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.113","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}